Tafinlar + Mekinist

Active substance

 Dabrafenib  + Trametinib

Holder

 Novartis Pharma

Status

Closed

Indication

 adjuvant treatment of high-risk BRAF V600 mutation-positive stage III melanoma after complete surgical resection

Public documents

Approbation

Information for the patient

Informed consent 

Last update

05/08/2019
Last updated on 13/09/2024